Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
-
- Brenda Weigel
- University of Minnesota; Minneapolis Minnesota
-
- Suman Malempati
- Department of Pediatrics; Oregon Health & Science University; Portland Oregon
-
- Joel M. Reid
- Mayo Clinic and Foundation; Rochester Minnesota
-
- Stephan D. Voss
- Children's Hospital-Boston and Dana Farber Cancer Institute; Boston Massachusetts
-
- Steven Y. Cho
- Johns Hopkins Hospital; Baltimore Maryland
-
- Helen X. Chen
- National Cancer Institute; Rockville Maryland
-
- Mark Krailo
- Department of Preventive Medicine; USC Keck School of Medicine; Los Angeles California
-
- Doojduen Villaluna
- Children's Oncology Group Operations Center; Monrovia California
-
- Peter C. Adamson
- The Children's Hospital of Philadelphia; Philadelphia Pennsylvania
-
- Susan M. Blaney
- Texas Children's Cancer Center/Baylor College of Medicine; Houston Texas
書誌事項
- タイトル別名
-
- Phase 2 Study of Cixutumumab
- 公開日
- 2013-08-17
- 権利情報
-
- http://doi.wiley.com/10.1002/tdm_license_1.1
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/pbc.24605
- 公開者
- Wiley
この論文をさがす
収録刊行物
-
- Pediatric Blood & Cancer
-
Pediatric Blood & Cancer 61 (3), 452-456, 2013-08-17
Wiley